Similar articles for PMID: 30770612

Year	Number of Results
1983	1
1985	1
1994	2
1996	1
1997	3
1998	2
1999	2
2000	1
2001	3
2002	3
2003	3
2004	2
2005	4
2006	7
2007	3
2008	4
2009	1
2010	4
2011	4
2012	9
2013	7
2014	2
2015	11
2016	6
2017	3
2018	6
2019	2
2020	3
2023	1
2024	0

1

Nested case-control study investigating the diagnostic role of tissue eosinophilia in adverse cutaneous drug reactions.

Samuelov L, Nathan A, Slutsky E, Fruchter D, Gat A, Sprecher E, Goldberg I. Samuelov L, et al. J Eur Acad Dermatol Venereol. 2019 Jun;33(6):1152-1157. doi: 10.1111/jdv.15509. Epub 2019 Mar 11. J Eur Acad Dermatol Venereol. 2019. PMID: 30770612

2

Role of peripheral eosinophilia in adverse cutaneous drug reactions.

Drago F, Cogorno L, Agnoletti AF, Parodi A. Drago F, et al. Eur Rev Med Pharmacol Sci. 2015;19(11):2008-9. Eur Rev Med Pharmacol Sci. 2015. PMID: 26125262 Free article.

3

Inpatient adverse cutaneous drug eruptions and eosinophilia.

Romagosa R, Kapoor S, Sanders J, Berman B. Romagosa R, et al. Arch Dermatol. 2001 Apr;137(4):511-2. Arch Dermatol. 2001. PMID: 11295947 No abstract available.

4

Tissue eosinophilia: not an indicator of drug-induced subacute cutaneous lupus erythematosus.

Hillesheim PB, Bahrami S, Jeffy BG, Callen JP. Hillesheim PB, et al. Arch Dermatol. 2012 Feb;148(2):190-3. doi: 10.1001/archdermatol.2011.290. Epub 2011 Oct 17. Arch Dermatol. 2012. PMID: 22004879

5

Eosinophils in severe sepsis in northern australia: do the usual rules apply in the tropics?

Pitman MC, Anstey NM, Davis JS. Pitman MC, et al. Crit Care Med. 2013 Oct;41(10):e286-8. doi: 10.1097/CCM.0b013e3182923755. Crit Care Med. 2013. PMID: 24060789

6

A retrospective study of cutaneous drug reactions in an outpatient population.

Drago F, Cogorno L, Agnoletti AF, Ciccarese G, Parodi A. Drago F, et al. Int J Clin Pharm. 2015 Oct;37(5):739-43. doi: 10.1007/s11096-015-0134-z. Epub 2015 Jun 7. Int J Clin Pharm. 2015. PMID: 26050251

7

Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).

Ogawa K, Morito H, Hasegawa A, Daikoku N, Miyagawa F, Okazaki A, Fukumoto T, Kobayashi N, Kasai T, Watanabe H, Sueki H, Iijima M, Tohyama M, Hashimoto K, Asada H. Ogawa K, et al. J Dermatol Sci. 2013 Jan;69(1):38-43. doi: 10.1016/j.jdermsci.2012.10.002. Epub 2012 Oct 26. J Dermatol Sci. 2013. PMID: 23141052

8

Drug reaction with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases.

Walsh S, Diaz-Cano S, Higgins E, Morris-Jones R, Bashir S, Bernal W, Creamer D. Walsh S, et al. Br J Dermatol. 2013 Feb;168(2):391-401. doi: 10.1111/bjd.12081. Br J Dermatol. 2013. PMID: 23034060

9

In vitro interleukin-5 (IL-5) production by peripheral blood mononuclear cells from patients with drug hypersensitivity.

Mikami C, Ochiai K, Kagami M, Tomioka H, Tanabe E. Mikami C, et al. J Dermatol. 1996 Jun;23(6):379-81. J Dermatol. 1996. PMID: 8708148

10

Tissue eosinophilia as an indicator of drug-induced cutaneous small-vessel vasculitis.

Bahrami S, Malone JC, Webb KG, Callen JP. Bahrami S, et al. Arch Dermatol. 2006 Feb;142(2):155-61. doi: 10.1001/archderm.142.2.155. Arch Dermatol. 2006. PMID: 16490843

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

97 results

Results by year